Structural and functional characterization of liposomal recombinant hepatitis B vaccine

Journal of Liposome Research

Volumn 6, Issue 2, 1996, Pages 289-304

  Diminsky, Dvorah ^a   Reimann, Z Jorg ^b   Schirmbeck, Reinhold ^b   Barenholz, Yechezkel ^a  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; HEPATITIS B SURFACE ANTIGEN; LIPOSOME; RECOMBINANT HEPATITIS B VACCINE;

ANIMAL CELL; ANTIBODY TITER; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; FREEZE DRYING; GLYCOSYLATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; LIPID VESICLE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VACCINATION;

EID: 0029886932     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.3109/08982109609031118     Document Type: Review

References (33)

1. Zuckerman, A.J. 1986. Novel hepatitis B vaccines. J. Infect. 13: 61.
2. Butterly, L., Watkins, E. and Dienstag, J.L. 1989. Recombinant yeast derived hepatitis B vaccine in healthy adults: Safety and two year immunogenicity of early investigative lots of vaccine. J. Med. Virol. 27: 155.
3. Shouval, D., Ilan, Y., Adler, R., Deepen, R., Panel, A., Even-Chen, Z., Gorecki, M. and Gerlich, W.H. 1994. Improved immunologenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast derived vaccines. Vaccine 12:1543.
4. Rutgers, T., Cabezon, T. and De Wilde, M. 1990. Production of viral antigens in prokaryotic and eukaryotic cells. In "Immunochemistry of Viruses II. The Basis for Serodiagnosis and Vaccines". M.H.V. Van Regenmortel and A.R. Neurath (Eds.). Elsevier, New York, p. 103.
5. Even-Chen, Z., Drummer, H., Levanon, A., Panet, A. and Gorecki, M. 1990. Development of novel hepatitis B vaccine containing Pre-S1, In "Biologicals from Recombinant Microorganisms and Animal Cells". M.D. White, S. Reuveny and A. Shafferman (Eds.). Balaban Publishers, Weinheim, p. 533.
6. Diminsky, D., Even-Chen, Z. and Barenholz, Y. 1993. Preparation and characterization of stable liposomal hepatitis B vaccine. In "New Generalion Vaccines: The Role of Basic Immunology". G. Gregoriadis, B. McCormick, A.C. Allison and G. Poste (Eds.). Plenum Press, New York, p. 51.
7. Pfaff, E., Klinkert, M.Q., Theilmann, L. and Schaller, H. 1986. Characterization of large surface proteins of hepatitis B virus by antibodies to preS-S encoded amino acids. Virology 148: 15.
8. Neurath, A.R. and Thanavala, Y. 1990. Hepadnaviruses. In "Immunochemistry of Viruses II. The Basis for Serodiagnosis and Vaccines". M.H.V. Van Regenmortel and A.R. Neurath (Eds.). Elsevier, New York, p. 403.
9. Shouval, D., Ilan, Y., Hourvitz, A., Mosseri, R., Solomon, A., Zychowicz, C, Gornicki, J., Czubkowska, I., Madalinski, K., Burczynska, B., Adler, R., Gorecki, M. and Koren, R. 1994. Immunogenicity of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S2 and pre-S1 antigens. A preliminary report. In "Viral Hepatitis and Liver Disease". K. Hishioka, H. Suzuki, S. Mishiro and T. Oda (Eds.). Springer-Verlag, Tokyo, p. 543.
10. Milich, D.R., McLachlan, A., Chisari, F.V., Kent, B.H. and Thornton, G.B. 1986. Immune response to the Pre-S(1) region of hepatitis B surface antigen (HBsAg): A Pre-S(1) specific T cell response can bypass non-responsiveness to the Pre-S(2) and S regions of HBsAg. J. Immunol. 137: 315.
11. Hemmerling, A.E., Muller, R., Firusian, N., Grotz, J., Haubitz, M. and Thoma, H.A. 1994. Clinical experience with the pre-S1-containing hepatitis B vaccine (HG-3) in different nonresponder groups. In "Viral Hepatitis and Liver Disease". K. Hishioka, H. Suzuki, S. Mishiro and T. Oda (Eds.). Springer-Verlag, Tokyo, p. 540.
12. Schirmbeck, R., Melber, K., Mertens, T., Reimann, J. 1994. Selective stimulation of murine cytotoxic T cell and antibody responses by particulate or monomeric hepatitis B virus surface (S) antigen. Eur. J. Immunol. 24: 1088.
13. + cytotoxic T lymphocyte responses in vivo. J. Immunol. 152: 1110.
14. Schirmbeck, R., Melber, K., Mertens, T. and Reimann, J. 1994. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: Implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 68:1418.
15. Alving, C.R. 1991. Liposomes as carriers of antigens and adjuvants. J. Immunol. Meth. 140: 1.
16. Alving, C.R. 1993. Immunological presentation of liposomal antigens. J. Liposome Res. 3: 493.
17. Gregoriadis, G. 1990. Immunological adjuvants: a role for liposomes. Immunol. Today 11: 89.
18. Storm, G., Oussoren, C., Peters E.M. and Barenholz Y. 1993. Tolerability of liposomes in vivo. In "Liposome Technology", Vol. III, 2nd ed. Gregoriadis, G. (Ed.). CRC Press, Boca Raton, FL, p. 345.
19. Lichtenberg, D. and Barenholz, Y. 1988. Liposomes: Preparation, characterization and preservation, In "Meth. Biochem. Anal." D. Glick (Ed.). Wiley, New York, Vol. 33, p. 337.
20. Barenholz, Y. and Crommelin, D. 1994. Liposomes as pharmaceutical dosage forms, In "Encyclopedia of Pharmaceutical Technology", Vol. 9, J. Swarbrick and J.C. Boylan (Eds.). Marcel Dekker, New York, p. 1.
21. Senior J.H. 1987. Fate and behavior of liposomes in vivo: A review of controlling factors. Crit. Rev. Therapeut. Drug Carrier Systems 3: 123.
22. Silvius, J.R. 1982. In "Lipid Protein Interactions", P.C. Jost and O.H. Griffith (Eds.). Vol. 2, Wiley, New York, Chapter 7.
23. Barenholz, Y. and Amselem, S. 1993. Quality control assays in development and clinical use of liposome based formulations, In "Liposome Technology", Vol I, 2nd ed. G. Gregoriadis (Ed). CRC Press, Boca Raton, FL, p. 527.
24. Kates, M. 1986. In "Techniques of Lipidology: Isolation, Analysis and Identification of Lipids." R.H. Burdon and P.H. Van Knippenberg (Eds.). Elsevier, Amsterdam, p. 326.
25. Carolyn, E.M. and Wright, L.C. 1988. Organization of lipids in the plasma membranes of malignant and stimulated cells: A new model. TIBS 13: 172.
26. Fielding, P.E. and Fielding, C.J. 1991. Dynamics of lipoprotein transport in the circulatory system. In "Biochemistry of Lipids, Lipoproteins and Membranes". D.E. Vance and J. Vance (Eds.). Elsevier, Amsterdam, p. 427.
27. Barenholz, Y., Pal, R. and Wagner, R.R. 1993. Metabolic labeling of viral membrane lipids by fluorescent fatty acids: Studying virus fusion with target membranes. In Meth. Enzymol. 220, "Membrane Fusion Techniques", Part A. N. Duzgunes (Ed.). Academic Press, San Diego, p. 288.
28. Gregoriadis, G., Wang, Z., Barenholz, Y. and Francis, M.J. 1993. Liposome-entrapped T-cell peptide provides help for a co-entrapped B-cell peptide to overcome genetic restriction in mice and induce immunological memory. Immunology 80: 535.
29. Davis, H.L., Michel, M. and Whalen, G. 1994. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and a high level of circulating antibody. Hum. Mol. Genet. 2: 1847.
30. Sujisawa, T., Itow Sasadar Onow et. al. 1983. Direct expression of HBsAg gene in E. coli. Nucleic Acid Res. 11:3581.
31. Gluck, R., Mischler, R., Brantschen, S., Just, M., Althous, B. and Cryz, S.J., Jr. 1992. Immunopotentiating reconstituted influenza virus virosomes, vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90: 2491.
32. Gluck, R., Mischler, R., Finkel, B., Que, J.U., Scarpa, B. and Cryz, S.J., Jr. 1994. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344: 160.
33. Stover, C.K. 1994. Recombinant vaccine delivery systems and encoded vaccines. Curr. Opinion Biol. 6: 568.